Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

@article{Blanc2008MesenchymalSC,
  title={Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study},
  author={Katarina Le Blanc and Francesco Frassoni and Lynne M. Ball and Franco Locatelli and Helene Roelofs and Ian Lewis and Edoardo Lanino and Berit Sundberg and Maria Ester Bernardo and Mats Remberger and Giorgio Dini and R. Maarten Egeler and Andrea Bacigalupo and Willem Fibbe and Olle Ringd{\'e}n},
  journal={The Lancet},
  year={2008},
  volume={371},
  pages={1579-1586}
}

Figures and Tables from this paper

The use of mesenchymal stem cells in therapy of steroid-resistance chronic refractory graft-versus-host disease after hematopoietic stem cell transplantation
TLDR
Reports of two cases of use of third-party donor mesenchymal stem cells in the therapy of steroid-resistant chronic GVHD show administration of MSC is a safe method and might by an effective therapy for patients with chronic refractory GV HD.
Mesenchymal stem cells targeting the GVHD
TLDR
The utility of MSCs for the treatment of GVHD is becoming clear and the recently elucidated immunosuppressive potential of mesenchymal stem cells has set the stage for their clinical testing as cellular Immunosuppressants.
Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease Using Commercial Mesenchymal Stem Cell Products
TLDR
A meticulous comparison of studies of remestemcel-L and Temcell, remesteemed-L/Temcell and ruxolitinib, and remestercel- L/Tem cell and thymoglobulin showed that the precise position of remESTem Cel-L /Temcell therapy in the treatment of acute GVHD remains to be determined.
Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases
TLDR
These patients with acute steroid-refractory GVHD who underwent allogeneic HSCT received infusions of third-party clonal mesenchymal stem cells (cMSCs), which were isolated by a subfractionation culturing method (SCM), and showed marked improvement of the disease.
Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study
  • H. Yi, S. Yahng, Sun U. Song
  • Medicine, Biology
    The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology
  • 2016
TLDR
This study demonstrates single cMSC infusion to have an acceptable safety profile and promising efficacy, suggesting that it can proceed with the next stage of the clinical trial.
Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
  • K. Zhao, R. Lou, Qifa Liu
  • Medicine, Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2015
Effective Treatment of Severe Steroid-Resistant Acute Graft-Versus-Host Disease With Umbilical Cord-Derived Mesenchymal Stem Cells
TLDR
These findings suggested that UCMSC were effective for treating severe steroid-resistant aGVHD, and these cells would appear to be the ideal candidates for clinical cell-based therapies.
Clinical Translation of Mesenchymal Stromal Cell Therapy for Graft Versus Host Disease
TLDR
The immunomodulatory properties supporting the therapeutic use of MSCs in GVHD are discussed and critical parameters for the clinical translation of MCSs, including consistent production of M SCs according to Good Manufacturing Practices (GMPs) and informative potency assays for product quality control (QC), are addressed.
Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study
TLDR
The data support the use of MSC infusions as treatment for steroid‐refractory cGvHD with durable responses, and propose CXCL9 and CxCL10 as early biomarkers for responsiveness to MSC treatment.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease
TLDR
MSC is a very promising treatment for severe steroid-resistant acute GVHD and five patients are still alive between 2 months and 3 years after the transplantation and their survival rate was significantly better than that of 16 patients with steroid- resistant biopsy-proven gastrointestinal GV HD, not treated with MSC during the same period.
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells
TLDR
Co-transplantation of MSC resulted in fast engraftment of absolute neutrophil count and platelets and 100% donor chimerism, even in three patients regrafted for graft failure/rejection.
Treatment of severe acute graft‐versus‐host disease with anti‐thymocyte globulin
TLDR
Treatment of severe acute GVHD is difficult and ATG, in the hands, adds nothing to conventional pharmacological treatment, according to results in 29 patients using ATG.
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
  • H. Lazarus, O. Koç, A. Bacigalupo
  • Medicine, Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2005
How I treat refractory acute GVHD.
TLDR
It is difficult to conduct controlled prospective trials in the setting of steroid-refractory GVHD, and a custom-tailored therapy dependent upon the time after HCT, specific organ manifestations of GV HD, and severity is appropriate.
Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation.
TLDR
The data suggest that MSCs, possibly thanks to their potent immunosuppressive effect on alloreactive host T lymphocytes escaping the preparative regimen, reduce the risk of graft failure in haploidentical HSC transplant recipients.
Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation.
  • K. Le Blanc, O. Ringdén
  • Medicine, Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2005
Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone
TLDR
Allogeneic mesenchymal cells offer feasible posttransplantation therapy for osteogenesis imperfecta and likely other disorders originating in mesenchyal precursors, including bone, cartilage, and muscle.
Human mesenchymal stem cells modulate allogeneic immune cell responses.
TLDR
Insight is offered into the interactions between allogeneic MSCs and immune cells and mechanisms likely involved with the in vivo MSC-mediated induction of tolerance that could be therapeutic for reduction of GVHD, rejection, and modulation of inflammation.
...
1
2
3
4
...